Tumor heterogeneity has been compared with Darwinian evolution and survival of the fittest. The evolutionary ecosystem of tumors consisting of heterogeneous tumor cell populations represents a considerable challenge to tumor therapy, since all genetically and phenotypically different subpopulations have to ...
Read More »
from Pharmabiz.com by Laxmi Yadav Positive Bioscience, India’s leading genomics company offering personal genomics and cancer genomics products, plans to launch more than 200 personalised genetic testing facilities across the country over a span of three years. The objective is ...
Read More »
Mainz University Medical Center coordinates new interdisciplinary collaborative research project / Findings will be used to improve cancer therapy, German government provides approximately EUR 3.8 million in financing Johannes Gutenberg Universitaet Mainz This article is available in German. Some individuals ...
Read More »
CHICAGO, March 2, 2015 (GLOBE NEWSWIRE) — NantHealth and Allscripts (Nasdaq:MDRX) will collaborate on the development and delivery of cutting-edge, precision medicine solutions directly to the point of care. The companies will introduce an integrated, evidence-based, personalized approach to ...
Read More »
PHOENIX, Ariz. – Sept. 10, 2014 – Dell, Terascala and the Translational Genomics Research Institute (TGen) are installing state-of-the-art computing and programing specialized for human genome investigations at the National Cancer Institute (NCI). As part of a formal collaboration, Dell ...
Read More »
from Medical Xpress Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open access journal Genome Biology. Because a tumor’s RNA shows the real time changes ...
Read More »
RNA-Seq Blog Transcriptome Research & Industry News
